From Wikipedia, the free encyclopedia
Chemical compound
Satavaptan
ATC code
N -(tert -butyl)-4-{[(1s ,4s )-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H )-yl]sulfonyl}-3-methoxybenzamide
CAS Number
PubChem
CID
ChemSpider
UNII
ECHA InfoCard
100.211.853
Formula C 33 H 45 N 3 O 8 S
Molar mass 643.80 g·mol−1 3D model (
JSmol )
C1COCCN1CCO[C@H]2CC[C@](CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+
N Key:QKXJWFOKVQWEDZ-VCCCEUOBSA-N
N
N Y
(what is this?)
(verify)
Satavaptan (
INN ; developmental code name SR121463 , former tentative brand name Aquilda ) is a
vasopressin-2 receptor antagonist
[1] which was investigation by
Sanofi-Aventis and was under development for the treatment of
hyponatremia . It was also being studied for the treatment of
ascites .
[2] Development was discontinued in 2009.
[3]
References
^ Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G (November 2006).
"Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist" . Clinical Journal of the American Society of Nephrology . 1 (6): 1154–60.
doi :
10.2215/CJN.00160106 .
PMID
17699341 .
^ Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D (July 2008).
"Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial" . Hepatology . 48 (1): 204–13.
doi :
10.1002/hep.22293 .
PMID
18508290 .
^
"Satavaptan" . Adis Insight . Springer Nature Switzerland AG.